Tehran Heart Center
Quick facts
Phase 3 pipeline
- Fludrocortisone Acetate Tablets · Endocrinology / Cardiovascular
Fludrocortisone acetate is a synthetic mineralocorticoid that enhances sodium reabsorption and potassium excretion in the distal renal tubules, thereby increasing blood volume and blood pressure. - Midodrine Hydrochloride Tablets · Cardiovascular
Midodrine is an alpha-1 adrenergic agonist that increases blood pressure by constricting blood vessels.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Tehran Heart Center
What is Tehran Heart Center's pipeline?
Tehran Heart Center has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Fludrocortisone Acetate Tablets, Midodrine Hydrochloride Tablets.
Related
- Sector hub: All tracked pharma companies